Financial Performance - Revenue for the six months ended September 30, 2021, was HKD 63,392,000, an increase of 54% compared to HKD 41,190,000 for the same period in 2020[6] - Gross profit for the same period was HKD 52,500,000, up from HKD 33,713,000, reflecting a gross margin improvement[6] - Operating profit decreased to HKD 228,000 from HKD 3,385,000, indicating challenges in operational efficiency[6] - The company reported a loss attributable to owners of the company of HKD 260,000, compared to a profit of HKD 2,810,000 in the previous year[6] - The company incurred a loss of HKD 209,000 during the six months ended September 30, 2021, compared to a profit of HKD 2,810,000 in the same period of 2020[12] - The group reported total revenue of HKD 63,392,000 for the six months ended September 30, 2021, compared to HKD 41,190,000 for the same period in 2020, representing a year-over-year increase of 54%[25] - Revenue from health supplements reached HKD 60,723,000, up from HKD 39,228,000 in the previous year, indicating a growth of 55%[26] - The group generated other income of HKD 484,000, significantly down from HKD 9,193,000 in the prior period, reflecting a decrease of approximately 95%[32] - The group’s pre-tax profit was impacted by a decrease in bank interest income, which fell to HKD 77,000 from HKD 698,000 year-over-year, a decline of 89%[32] - The total cost of inventory for the period was HKD 10,892,000, an increase from HKD 7,477,000 in the same period last year, representing a rise of 46%[36] - The group’s total tax expense for the six months ended September 30, 2021, was HKD 260,000, slightly down from HKD 261,000 in the prior year[38] Assets and Liabilities - Total assets as of September 30, 2021, were HKD 170,463,000, down from HKD 179,905,000 as of March 31, 2021[10] - Net asset value decreased to HKD 167,080,000 from HKD 176,227,000, indicating a decline in shareholder equity[10] - Current liabilities increased to HKD 31,040,000 from HKD 22,266,000, reflecting higher operational obligations[10] - The company’s total liabilities increased to HKD 12,121,000 as of September 30, 2021, from HKD 9,988,000 as of March 31, 2021[54] - The company’s receivables amounted to HKD 9,405,000 as of September 30, 2021, down from HKD 11,109,000 as of March 31, 2021[48] - The fair value of equity investments classified as other comprehensive income decreased to HKD 4,222,000 as of September 30, 2021, from HKD 5,506,000 as of March 31, 2021[45] - The company’s accounts payable increased significantly to HKD 4,120,000 as of September 30, 2021, from HKD 1,700,000 as of March 31, 2021[54] Cash Flow and Liquidity - The company’s cash and cash equivalents stood at HKD 85,239,000, an increase from HKD 59,987,000, indicating improved liquidity[10] - The net cash generated from operating activities was HKD 9,758,000 for the six months ended September 30, 2021, a decrease from HKD 15,734,000 in the prior year[15] - The company’s operating cash flow before changes in working capital was HKD 7,206,000, down from HKD 11,856,000 in the previous year[15] - The company reported a significant increase in cash and cash equivalents, totaling HKD 85,239,000 at the end of the period, compared to HKD 63,561,000 a year earlier, representing a growth of approximately 34%[15] Strategic Outlook - The company plans to focus on new product development and market expansion strategies in the upcoming periods[6] - Future outlook remains cautious due to market volatility and operational challenges faced during the reporting period[6] - The company plans to continue expanding its market presence in Hong Kong and enhance its product offerings in the health and personal care sector[17] - The group plans to strategically expand its physical sales network into prime retail locations and hire professional health consultants to enhance customer experience and drive sales[87] - The group is actively implementing various marketing initiatives, including attractive promotional activities and social media engagement, to attract new customers and improve customer loyalty[87] - The management acknowledges that the pandemic and other macroeconomic variables may affect the speed of market recovery but remains committed to providing quality products and services[87] Shareholder Information - The company did not declare an interim dividend for the six months ended September 30, 2021, compared to no dividend declared in 2020[42] - As of September 30, 2021, Beatitudes International Ltd. holds 425,340,000 shares, representing approximately 55.82% of the company's issued share capital[93] - Mr. Gao holds 89,225,000 shares, accounting for about 11.71% of the company's equity as of September 30, 2021[94] - Following a placement agreement, Beatitudes' shareholding decreased from 562,500,000 shares (approximately 73.82%) to 425,340,000 shares (approximately 55.82%) after the completion of the placement on September 13, 2021[93] - The average number of issued ordinary shares remained constant at 762,000,000 for both periods[43] - A total of 137,160,000 shares were successfully placed to 21 subscribers, resulting in 247,435,000 shares (approximately 32.47% of the company's issued share capital) held by public shareholders[105] - As of September 30, 2021, public holdings accounted for no less than 25% of the total issued shares[107] Corporate Governance - The company has complied with all provisions of the corporate governance code during the reporting period, except for the exception regarding the roles of the chairman and CEO[101] - The audit committee, composed of three independent non-executive directors, is responsible for reviewing and supervising the financial reporting system and internal control procedures of the group[108]
澳至尊(02031) - 2022 - 中期财报